Cellular Dynamics International Inc. is using induced pluripotent stem (iPS) cells, derived from adult cells, as drug discovery and development tools. The company is initially pursuing the cardiotoxicity market with iCell cardiomyocytes, which closely resemble in vivo cardiomyocytes, even beating in unison in a cell culture dish. When exposed to drugs or other external agents, the cells produce electrophysiological and biochemical responses typical of in vivo cardiomyocytes.
525 Science Drive
Madison, WI 53711
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The drugmaker presented data at a lymphoma meeting showing strong efficacy for the CAR-T in marginal zone lymphoma, the second most common indolent lymphoma.
The company presented Phase I data for CART-EGFR-IL13Rα2, showing patient responses in the notoriously hard-to-treat and deadly brain cancer.
Gilead’s Kite division presented Phase I data for its next-generation CAR-T therapy KITE-363 in patients with B-cell lymphomas.
The biotech believes its logic-gated cell therapies can get round the need for ‘clean targets’ which limit CAR-Ts and ADCs.
IGI CEO tells Scrip about the “very encouraging” feedback at ASCO to promising early data for the firm's first-in-class investigational trispecific antibody in multiple myeloma. Is a licensing deal in the offing?
Regenxbio reported functional and biomarker data from an ongoing study of RGX-202, which it hopes to file for approval in Duchenne muscular dystrophy in 2026.
Gilead’s Kite division presented Phase I data for its next-generation CAR-T therapy KITE-363 in patients with B-cell lymphomas.
